- Home
- GOF vs ARQT Comparison
GOF vs ARQT Comparison
Compare GOF & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- ARQT
- Stock Information
- Founded
- GOF 2006
- ARQT 2016
- Country
- GOF United States
- ARQT United States
- Employees
- GOF N/A
- ARQT N/A
- Industry
- GOF Finance/Investors Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- ARQT Health Care
- Exchange
- GOF Nasdaq
- ARQT Nasdaq
- Market Cap
- GOF 2.3B
- ARQT 2.1B
- IPO Year
- GOF N/A
- ARQT 2020
- Fundamental
- Price
- GOF $13.05
- ARQT $23.24
- Analyst Decision
- GOF
- ARQT Strong Buy
- Analyst Count
- GOF 0
- ARQT 7
- Target Price
- GOF N/A
- ARQT $22.17
- AVG Volume (30 Days)
- GOF 789.2K
- ARQT 2.6M
- Earning Date
- GOF 01-01-0001
- ARQT 10-28-2025
- Dividend Yield
- GOF 15.42%
- ARQT N/A
- EPS Growth
- GOF N/A
- ARQT N/A
- EPS
- GOF N/A
- ARQT N/A
- Revenue
- GOF N/A
- ARQT $317,929,000.00
- Revenue This Year
- GOF N/A
- ARQT $85.27
- Revenue Next Year
- GOF N/A
- ARQT $30.70
- P/E Ratio
- GOF N/A
- ARQT N/A
- Revenue Growth
- GOF N/A
- ARQT 129.21
- 52 Week Low
- GOF $10.96
- ARQT $8.90
- 52 Week High
- GOF $16.76
- ARQT $27.08
- Technical
- Relative Strength Index (RSI)
- GOF 37.82
- ARQT 54.57
- Support Level
- GOF $13.12
- ARQT $23.32
- Resistance Level
- GOF $13.35
- ARQT $24.39
- Average True Range (ATR)
- GOF 0.33
- ARQT 1.48
- MACD
- GOF 0.04
- ARQT -0.22
- Stochastic Oscillator
- GOF 16.39
- ARQT 48.73
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.